| |
Consumers are looking to improve their gut health and direct-to-consumer testing companies are investing in the opportunity. Discover key considerations and learn how to pick the best at-home fecal collection device in this free guide. Download Now. .png)
|
|
Today's Big NewsJan 27, 2023 |
|
Phreesia Life Sciences surveyed more than 4,300 patients checking in for their doctors’ appointments to better understand their perceptions and
preferences around clinical trials. But what's the best way to reach them? View Infographic 
|
|
| By James Waldron British biotech IPOs in 2022 dropped to their lowest levels in a decade, with the amount the sector raised also plummeting year over year. However, some hope may be on the horizon in the form of billions of pounds in fresh VC funds. |
|
|
|
By Nick Paul Taylor Celgene spinout Celularity has left an ax dangling over a “substantial portion” of its workforce. While the cell therapy firm is “hopeful” it can avoid significant layoffs, it has told many staffers their jobs are on the line as it pursues an updated strategy. |
By James Waldron Quince Therapeutics may have picked up a new leadership team, a rare disease focus and even a new name over the past year, but the biotech’s previous C-suite members clearly have some unfinished business. Under the guise of Lighthouse Pharmaceuticals, they’ve returned to pick up Quince’s unwanted protease inhibitor portfolio. |
Sponsored by Clarify Health We initiate a discussion focused on the relation of clinical trials and the need for geographical inclusion versus societal exclusivity. With some trial sites including only 20% of the disease population in the United States, innovation is needed. |
By Nick Paul Taylor And then there were two. Senti Bio, seeing the end of its cash runway hove into view, has pulled the plug on its liver cancer candidate and narrowed its focus onto two CAR-NK programs to preserve its money. |
By Gabrielle Masson Altamira Therapeutics’ plan to sell subsidiary Zilentin and its inner ear R&D work in efforts to become a “pure play” RNA company have grown murky, as the proposed buyer has failed to come up with the money. |
By Helen Floersh Amid new policies to make research publications more readily available to both scientists and the public, stakeholders from an international cohort of universities signed off on a set of practices to monitor accessibility in biomedical research. They also committed to tracking their institutions’ adherence to the new guidelines on a digital dashboard. |
By Gabrielle Masson XyloCor Therapeutics’ lead candidate, a one-time gene therapy dubbed XC001, has met both safety and efficacy goals among 28 patients with refractory angina. |
By Ben Adams When it comes to using new drug technology doctors can sometimes be a little conservative, but for next-gen mRNA tech physicians appear to be all-in. |
By Andrea Park Synchron and Elon Musk’s Neuralink are currently leading the brain-computer interface pack, but a potential competitor has emerged complete with tens of millions of dollars in financing and a former Neuralink executive at the helm. |
By Fraiser Kansteiner This week, the FDA nixed Evusheld’s emergency nod for prevention of COVID-19. The regulator noted AZ’s prophylactic has lost effectiveness in the face of circulating SARS-CoV-2 variants. |
By Frank Diamond A panel of experts that advises the FDA approves a one-shot approach in which all COVID-19 vaccines would be used to formulate boosters. |
By Max Bayer,Gabrielle Masson J&J CMO announces retirement after 20-year executive run. Vir taps Bayer dealmaker to replace outgoing CEO Scangos. Vividion promotes R&D chief to CEO. |
By Angus Liu Takeda has bought into a Hutchmed cancer drug in a deal potentially worth more than $1 billion. BeiGene's Brukinsa earned a key FDA approval in chronic lymphocytic leukemia. An Astellas gene therapy candidate has come off an FDA clinical hold. And more. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we hear from Stacie Dusetzina, Ph.D., a professor at Vanderbilt University's Department of Health Policy, about what the IRA means for the pharma industry. We'll also discuss what we can expect from the biotech industry in 2023. |
|
|---|
|
|
|
March 14-15, 2023 | San Francisco, CA Be in the room with the life sciences industry leaders to forge new connections & take advantage of in-person networking opportunities. Register now to be in the room for this amazing networking opportunity! 
|
|
Whitepaper RCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
